



irradiating a target tissue or organ in said individual; and
administering to said individual a biodegradable particle
comprising antibodies or antibody fragments that bind to P-selectin
or ICAM-1 expressed on an endothelial cell, and a pharmaceutical.

Please amend claim 7 as follows:

7. (amended) The method of claim 6, wherein said
pathophysiological state is selected from the group consisting of
cancer.

REMARKS

Status of the Claims

Claims 1-7 are pending. Claims 1-5 are withdrawn from
consideration. Claims 6-7 are rejected. Claims 6-7 are amended.

Attached hereto is a marked-up version of the changes
made to the specification and claims by the current amendments.
The attached page is captioned "VERSION WITH MARKINGS TO
SHOW CHANGES MADE". No new matter has been added.
Reconsideration of the pending claims is respectfully requested.

RECEIVED
JAN 24 2003
TECH CENTER 1600/2900